Nicola CEO Reza will trust to close the deal with the partner, rising 12%


Goldsmith Sachs predicts a rally of more than 40% for these 3 stocks

A new wave of optimism is flooding the street. Investment firm Goldm Sachs forecasts its three-month stock, rising from neutral to overweight, and also presents a “high single-digit return” for global stocks in the coming year. What is behind this improved approach? Goldman Sachs strategist Christian Mailer-Glissman cites impressive reductions in global earnings growth and reduced equity costs as drivers of estimated improvement. On top of this, a “broader proactive shift” in shares and other assets could occur during the rest of this year. “We have shifted more cyclically to areas and themes, but the strategy still prefers value versus growth on the horizon.” In the near term, U.S. Non-US equities may benefit more from the increased uncertainty and better global growth outlook on the election, but medium-term structural growth is likely to support the S&P 500, which weighs heavier in stocks, “noted Mueller-Glissman. For the “most important catalyst” that could stimulate optimism, strategists are looking for additional clarification on when and how the Covid-19 vaccine will be available. According to these analysts, every name is poised to rise in the next 12 months. Before Raytheon Technologies (RTX) we have Raytheon Technologies, an aerospace and defense company that serves commercial, military and government customers. The stock stumbled in 2020, while Goldm Sachs thinks the weakness presents an opportunity to buy. Analyst Noah Poponak, who presented the payday, said: RTX is in high quality and in good condition to trade in 11% free cash flow cash yield. Complete aerospace-recovered recovered and full coincidence of 2023E free cash. “Analysts’ bullish outlook is largely driven by the company’s post-aerospace market (a secondary market that deals with the installation of after-sales equipment for equipment, spare parts, accessories and parts. Original equipment manufacturer) business, within which Poponak argues that” aerospace Is the best sub-market of the period. “This segment accounts for about 45% of RTX’s aerospace revenue. Although this is part of the business of COVID-19 flight interruptions, Poponak said total aircraft in service are only 25% down year-on-year, and Flights have dropped by less than 50%. He added, “China’s domestic traffic is now up year-on-year, and while international frustration remains, we expect global air travel to recover from here by 203-20-201 by. Recovery may be faster than widely expected. “Poponak highlights that in the past, downturns faced headwinds in the aftermarket market that resulted from increasing use of delays in sharing, inventory pooling, and subsequent costs.” After all, the post-ASM market has grown or accelerated, and we believe this is a demand to move towards a recession that tracks recovery recovery in global air travel. In the long run, we expect air traffic to grow at 2X global GDP, as it has historically, “the analyst commented. Given the good news, the gear turbo fan, which is a type of turbof urb aircraft engine, produces significant revenue. And according to Popnak, EBIT growth at Pratt & Whitney. “Given the high OI exposure of the A320 annu, which has a strong backlog of any aircraft on the market, we see that Pratt Oi’s revenue is catching up better and improving faster than Pierce’s. Is. The new GTF will expand the established base for delivery prat, which had been declining for most of the 2000s. Despite the end of the V2500 OI delivery, the program is only moving to Sweet Spot for aftermarket store visits, ”says Poponak. What’s more, Poponak sees merger synergies as capable of fueling margin expansion and cash generation with fuel history. Is. The consistency capture in space suggests that the upside of guidance is not out of the question. With their optimistic approach, Poponak stays with the bull. For this, it keeps a buy rating on the stock and a price of $ 86. Investors can increase by 49% if this target is met in the next twelve months. (To see Poponak’s track record, click here) In general, other analysts echo Poponnak’s sentiment. 7 Buy and 2 Holds add to Strong Buy Consensus Rating. With an average price target of 78.63, the probability of a side fall is 36.5%. (See RTX Stock Analysis on Tipperenx) Moving on to another player in Boeing (BA) aerospace space, Boeing has also struggled with the Covid-1p epidemic, as it has failed to gain momentum in the wider market. That being said, Goldman Sachs hopes to move the name forward. Firm analyst Noah Poponak, who also covers RTX, points out that B.A. Covid has streamlined production rate plans by half compared to the top plan before the crisis and the Max. Grounding. Expected air travel may result in more reductions than expected, but analysts have argued that these reductions will be much smaller than those already witnessed. He added, “Historically, excellent buying opportunities in BA stocks are appropriate when it has brought down the rate of production.” Compared to the previous economic downturn, according to Poponak, the current recession is the highest and fastest in the current recession, although this is partly related to the grounding of 737 MAX in 2019. “We believe this will lead to less severe disruption of supply and demand balances, and improve global air travel and change airlines’ accelerated retirements to 2018 levels by 2024.” “The answer is that airlines are improving this mix during the recession,” Poponak said. “The answer is how the company can accomplish its new production rate plan. The combination of its backlog weighs more towards growth than replacement.” . ”Since the onset of the epidemic, airlines have announced high-end aircraft retirement plans, and braced for low growth. “This means that for the improvement in the airline’s order book, there is also a significant mix shift from growth to change in the number of new deliveries. Therefore, the backlog will not necessarily lose all of its growth orders, “the analyst said. In general, the pace has slowed following an increase in aircraft order cancellations in March and April.” Also, we estimate that by the middle of the decade, production of 737 MEX will be about 6X years on our revised production rate estimates, “when it comes to free cash flow, analysts are also optimistic, with Poponak predicting a positive free cash flow in BA 2021. “We feel that the market is underestimating the cash margin of the mid-cycle acquisition aircraft unit in large applications, temporarily expanding the negative things in the future, and underestimating the degree of inventory in 2021,” he said. “If that wasn’t enough, MAX’s recovery could be a potential catalyst. The company is working to recover and return to service, while Poponak is expected to arrive before the end of both years,” he said. Is eaten. With all of the above in mind, Poponak aims for a rating and 5 225. This goal shows BA’s confidence in its ability to climb 35% more in the coming year. Turning to the rest of the analyst community, opinions are mixed. With 8 buy, 8 hold and 1 sell assigned in the last three months, the word on the street is that BA is a moderate buy. . At 192.40, the average price target indicates a 16% side upside potential. (See Boeing Stock Analysis on Tipranx) Immetics (IMTX) With the discovery of the right target for cancer immunity (therapies that use the immune system), with the development of T cell receptors, Emitix hopes to finally achieve a stronger and Specific T cell response. Based on his sophisticated approach, Goldman Sachs considers himself a fan. Greg Suvannawage, an analyst for PayAll, notes that unlike the CAR-T approach, the T cell receptor (TCR) -based approach can go beyond targets within the cell, and fight 90% of cancers that are solid tumors in nature. The company is advancing two technologies: actinogen, designed for individual TCR-based cell therapy targeting TTCR-based bipolar antibodies, and TCER. ACTNGIN is a more advanced technology, with its four properties IMA201, targeting the genetically engineered T cell production candidate or melanoma-related antigen 4 or 8, IMA202, which targets melanoma-related antigen 1, IMA203. (PRAME) and IMA204 primarily target the antigen COL6A3 (found in a tumor stroma and very prevalent in tumor microenvironments) in a wide range of cancers / TME) expected to enter the clinic soon. Using the TCER platform, IMTX is developing IMA 401 and IMA 402, or “out of the shelf” biologics with a portion of TCR that directly identifies cancer cells and a T cell recruitment domain that recruits and activates the patient’s T cells. Is. In his search for market opportunity, Suvannavej noted that the advances he has seen over the past decade, and in particular, with CAR-T, have paved the way for cell therapy-based approaches … However, CAR-T is, so far, limited to cancer treatment. The effect is shown to be a solid lump in nature. With more than 0% solid tumors in all cancers – lung, breast, colorectal and prostate cancers account for c ..% of the total – this is an opportunity for IMTX. “For this, they believe that sales for actinogen-based assets could reach .5 15.5 billion by 2035. Choosing another positivity, IMTX has entered into at least one significant partnership each year with the top global biopharma companies. Military funding opportunities have been provided, the analyst added. Dedicated Institutional Investors. Together, we recognize this as recognizing the long-term prospects of IMTX. ”Looking ahead, initial clinical data readouts for IMA 2017, IMA 202 and IMA 203, prepared for Q1 2021, and investigations for IMA 204 The new drug (IND) application submissions and IMA 401 reflect, in the opinion of Suvarnavej, 2021 and YE2021, respectively, the main potential catalysts. He promised to repeat his buy rating. With KL, he set a price target of 17, indicating a 73% potential. (To view Suvannawaj’s track record, click here) Do other analysts agree? They are. In fact, only Buy Ratings, 4, has been issued in the last three months. So, the message is clear: IMTX is a strong buy. Given the average price target for the 19th average, the stock could rise to 93% in the coming year. (See Emmetics Stock Analysis on Tipranx) To find good ideas for trading stocks at attractive valuations, visit Tipranx’s Best Stock to Buy, which unites all of Tipranx’s equity insights. DISCLAIMER: The views expressed in this article are those of the distinguished analysts. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment.